Industry & Business

BioMarin expands facility to manufacture medicine for rare genetic diseases

 Breaking News
  • Research Reveals SMEs Lose €2.2 Billion a Year in Productivity Due to Administration Sage, a market leader in cloud accounting software, has revealed that Irish SMEs lose up to €2.2 billion annually in productivity due to burdensome administrative tasks. The report, ‘Sweating the Small Stuff: the impact of the bureaucracy burden’, undertaken by Plum Consulting, shows businesses in Ireland spend an average of 70 working-days per year navigating the [...]...
  • European Commission Takes Action For a More Competitive and Innovative Financial Market The European Commission has unveiled an Action Plan on how to harness the opportunities presented by technology-enabled innovation in financial services (FinTech). Europe should become a global hub for FinTech, with EU businesses and investors able to make most of the advantages offered by the Single Market in this fast-moving sector. As a first major deliverable, [...]...
  • 40% Think Irish Government Not Doing Enough to Protect Ireland From Impact of Brexit Brexit is coming closer and still a lot of questions remain unanswered. People are insecure not only about their own future but also the economic future of Ireland. iReach Insights conducted a nationally representative survey and 1,000 adults were asked about their opinion about the Brexit, it’s potential impact and what Irish people would do, [...]...
  • Guinness Remains Ireland’s Most Valuable Brand at €2.1 Billion Guinness remains Ireland’s most valuable brand after growing by 5% over the last year to a brand value of €2.1 billion on the back of new product innovations and steady sales of the world-famous draught, according to the latest report by Brand Finance, the world’s leading independent brand valuation and strategy consultancy. Guinness’s brand value has [...]...
  • Dún Laoghaire-Rathdown County Council Provides Over €742 Million For Future Development Dún Laoghaire-Rathdown County Council has agreed a Capital Expenditure Programme of over €742 million. The Three Year Capital Programme 2018-2020 will deliver a considerable number of infrastructural and housing projects that are of strategic importance to the County and the Region from both a social and an economic perspective. This will shape the development of [...]...

BioMarin expands facility to manufacture medicine for rare genetic diseases

BioMarin expands facility to manufacture medicine for rare genetic diseases
July 31
09:00 2017

Simon Coveney, Minister for Foreign Affairs and Trade, has officially opened a new expansion at BioMarin Pharmaceutical Inc. in Shanbally, Co Cork. BioMarin has recently extended its site footprint to 20 acres as the company continues to experience a rise in the global demand for its therapies to treat rare genetic diseases that mostly affect children.

Since opening its doors in 2011, the company has grown to 365 employees in Cork, with an additional 67 people based in Dublin and 2,400 employees globally. BioMarin focuses on developing first-­‐in-­class and best-­in-­class therapeutics that have the potential to improve clinical outcomes of patients with rare genetic diseases. The company currently has six approved products that are the only drugs available on the market today for the diseases they treat.

This expansion project began two years ago to cater for continued growth at the site and includes an expanded warehouse, new administration and utilities offices, a canteen and conference facilities. The overall project will allow the company to maximise the flexibility of the site with the expansion of the operational manufacturing capacity. The site will also see the installation of a Waste Water Treatment Plant later this year, while three new lab expansions are to be completed by Q3 2018.

Jean-­Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin stated: “Ireland has proved to be an ideal location to expand our operations. The team at Shanbally has enabled us to accommodate our growing commercial portfolio and advancing clinical programs. Mostly children, our patients suffer from diseases so rare that the entire afflicted population may number as few as 1,000 worldwide. Often inherited, difficult to diagnose, and progressively debilitating, these conditions have, up until now, been largely ignored. As we continue to grow in Shanbally, we are looking to recruit the best and brightest in a variety of disciplines to help us continue our inspiring work for patients.”

Welcoming the expansion, Simon Coveney said: “Today’s announcement represents a significant investment in the local economy. Shanbally is BioMarin’s only manufacturing facility outside the US and what they have done in such a few short years is very impressive. The company is continuing to grow and I understand that there are up to 50 open positions across a variety of departments at Shanbally waiting to be filled. BioMarin is a prime example of the high-­‐tech Life Sciences companies that this area of Cork has a reputation for.”

CEO of IDA Ireland Martin Shanahan said: “I am delighted that BioMarin continues to consolidate its commitment to its Irish operations in Shanbally. The company’s presence in Cork strengthens Ireland’s global reputation as a biopharmaceutical industry leader and brings high quality jobs to countless people across the south-­west region. We look forward to working closely with the company as it further develops its operations here.”

About Author



Related Articles

New Subscriber

Subscribe Here


National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories

Upcoming Events

  • No upcoming events
AEC v1.0.4